Today: 3. Jul, 2024
Half a decade ago, Moderna (MRNA) was a name that barely resonated in pharmaceutical circles. Focused on DNA-based drugs and vaccines, the company lingered on the periphery, largely overlooked by investors wary of speculative biotechnology ventures. Then came the seismic shock of…
Moderna announced on Wednesday its combined COVID and flu vaccine will proceed to the ultimate trial phase for adults aged 50 and above this year, following promising outcomes from preliminary to mid-phase research. To secure regulatory approval by 2025, Moderna’s mRNA-1083 shot…
The latest wave of COVID-19 vaccinations in the U.S. has encountered some stumbling blocks, particularly around delayed health insurance coverage for the vaccines. Private insurers, along with government-funded programs like Medicare, are obligated to cover the costs of the newly released Pfizer…
In the ever-evolving landscape of the stock market, healthcare stocks have consistently shown their resilience and potential for long-term growth. Among the top contenders in this sector are Johnson & Johnson (JNJ), Vertex Pharmaceuticals (VRTX), and Moderna (MRNA), each offering unique opportunities…
